MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.
Products, services, technology
Our lead product, MitoStemX, enhances T cell therapies against cancer and is now available for out-licensing. Looking ahead, we are actively developing Mito-66 for kidney fibrosis and MitoBrain for Alzheimer’s disease, tackling two of the most pressing unmet medical needs.
- https://www.mpc-therapeutics.com/
- Send an email
- Raphael Martinou
